Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri

Br J Cancer. 2023 Feb;128(3):439-440. doi: 10.1038/s41416-023-02146-9. Epub 2023 Feb 16.

Abstract

We discuss Pyrhönen's paper as a catalyst for defining systemic therapy approaches in gastric cancer and how the field has evolved in the last two decades in sequential, targeted and more recently immune-directed therapies and how it may develop to transform survival in this cancer of high unmet need.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Epirubicin
  • Fluorouracil / therapeutic use
  • Humans
  • Methotrexate / therapeutic use
  • Stomach Neoplasms* / drug therapy

Substances

  • Epirubicin
  • Fluorouracil
  • Methotrexate